Restrictive versus liberal transfusion in cardiac surgery
Which transfusion threshold best balances oxygen delivery and transfusion exposure in cardiac surgery? Compare trial populations, ischemic outcomes, mortality, and the actual thresholds used—not anemia alone.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 3 of 10 · Review
Recent evidence · past year
-
Perioperative hemostatic therapy in adult cardiac surgery: a narrative review highlighting human factors.
AI summary of the abstract, unverified
- This narrative review synthesizes fourteen original studies covering nearly 220,000 patients from over 1,000 centres worldwide.
- It focuses on platelet concentrate and fresh frozen plasma use in adult cardiac surgery and how hemostatic therapy varies between centres.
- Platelet and plasma transfusion rates differed significantly across centres, and patient and procedural characteristics do not fully explain these differences.
- Viscoelastic tests have improved assessment in some settings but have not eliminated variation, which the authors attribute partly to hospital culture, organization, thresholds and human factors.
Original abstract (PubMed)
Severe bleeding remains a significant cause of morbidity and mortality in cardiac surgery, and hemostatic blood components, mainly platelet concentrates and fresh frozen plasma, are essential to perioperative hemostatic management. While restrictive strategies for packed red blood cell transfusions are now well established within Patient Blood Management, inappropriate prophylactic transfusions of these hemostatic therapies continue to receive less attention.This narrative review investigates variations in hemostatic therapy among centres for adult cardiac surgery, and examines the factors that might explain these differences. A review of fourteen original studies involving nearly 220,000 patients from over 1,000 centres worldwide revealed significant variations in platelet and fresh-frozen plasma transfusion rates across centres.Differences in patient and procedural characteristics cannot entirely explain these variations. Although viscoelastic hemostatic tests have improved bedside assessment and lowered exposure in some settings, they have not eradicated significant variations in practice. The available evidence indicates that hospital culture, local organization, transfusion thresholds, and human factors all have an impact on transfusion behaviour.Optimizing the use of hemostatic therapies in adult cardiac surgery will therefore not only require better tools and protocols, but also increased focus on the organizational and non-technical factors that influence decision-making.
-
From liberal to restrictive and beyond: a narrative review of red blood cell transfusion strategies in the modern era.
AI summary of the abstract, unverified
- This narrative review of red blood cell transfusion thresholds draws on 2021–2026 trials, meta-analyses, and guidelines identified through PubMed and Google Scholar searches.
- It compares restrictive (Hb 7–8 g/dL) and liberal (Hb above 10 g/dL) strategies, then considers population-specific exceptions and ultra-restrictive thresholds (Hb <6–7 g/dL).
- The 2025 Cochrane update (48 trials, >20,000 participants) reported that restrictive strategies reduced the proportion receiving at least one transfusion by 41%, without increasing 30-day mortality or major morbidity.
- Restrictive thresholds appear safe in stable critically ill patients, non-cardiac surgery, and acute GI bleeding, while acute MI, neurocritical care, thalassemia, and hematologic malignancies need individualized approaches.
Original abstract (PubMed)
BACKGROUND: Red blood cell (RBC) transfusion remains a cornerstone of modern medicine, yet optimal transfusion thresholds continue to be debated. Historically, liberal strategies -maintaining hemoglobin (Hb) concentration above 10 g/dL- predominated, but evidence from the 1990s onward has favored restrictive approaches (Hb threshold 7-8 g/dL). This narrative review synthesizes contemporary evidence on restrictive versus liberal transfusion strategies published between 2021 and 2026, evaluates population-specific considerations, and explores emerging ultra-restrictive thresholds. MATERIALS AND METHODS: A structured narrative literature search was conducted in PubMed and Google Scholar with particular emphasis on evidence published between 2021 and 2026. Evidence from randomized controlled trials, systematic reviews, meta-analyses, and clinical practice guidelines is critically discussed. RESULTS: The 2025 Cochrane update (48 trials, >20,000 participants) provided high-certainty evidence that restrictive strategies induce a reduction in the risk or proportion of patients receiving at least one RBC transfusion by 41% without increasing 30-day mortality or major morbidity. Restrictive thresholds are safe in stable critically ill patients, in those undergoing non-cardiac surgery, and in patients with acute gastrointestinal bleeding. However, important exceptions include: acute myocardial infarction (in which liberal strategies may reduce cardiac events), neurocritical care (conflicting evidence on neurological outcomes), chronic transfusion-dependent conditions such as thalassemia (liberal strategies are disease-modifying), and hematologic malignancies (individualized approach required). Ultra-restrictive thresholds (Hb <6-7 g/dL) have emerged as a potential blood conservation tool during shortages but require further safety validation. DISCUSSION: Restrictive transfusion strategies are safe and effective for many stable adult hospitalized patients, reducing blood product utilization without compromising outcomes. However, individualized approaches remain essential for specific high-risk populations. Ultra-restrictive strategies are promising, but these approaches should currently be considered only in selected contexts pending further safety validation.
-
Coagulopathy in Cardiac Surgery: A Scoping Review of Prothrombin Complex Concentrate.
AI summary of the abstract, unverified
- This scoping review (PRISMA-ScR) mapped 57 primary studies and 15 reviews on 4-factor PCC in adults undergoing on-pump cardiac surgery.
- The comparator was FFP, and reported PCC dosing ranged from fixed 500-4000 IU to weight-based 15-30 IU/kg.
- Evidence consistently suggests PCC reduces chest tube output and transfusion versus FFP, though effect sizes vary; no pooled estimates are reported.
- The authors conclude that gaps remain on optimal dose, timing, viscoelastic targets, and fibrinogen sequencing, with limited cost-effectiveness data and rare serious adverse events.
Original abstract (PubMed)
BACKGROUND: Coagulopathy after cardiopulmonary bypass substantially contributes to postoperative bleeding, transfusion requirements, morbidity, and mortality. The traditional treatment option is fresh frozen plasma (FFP), but prothrombin complex concentrate (PCC) has become an alternative in the past years. AIM: This study aimed to systematically map the current evidence and identify critical knowledge gaps regarding the efficacy, optimal timing, dosing regimens, point-of-care testing guidance, administration order, cost-effectiveness, and safety of 4-factor PCC in adult patients undergoing on-pump cardiac surgery, thereby informing future research priorities. METHOD: A scoping review was conducted following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines. A search of several databases was conducted on 8 April 2025 without restrictions on the language or date of the publications. Study selection, data extraction, and charting were performed independently by two mutually blinded reviewers. RESULTS: A total of 57 primary studies (seven randomised controlled trials, 36 retrospective cohorts, five prospective cohorts, and nine experimental investigations) and 15 reviews with or without meta-analyses were identified. Evidence consistently indicates that PCC reduces postoperative chest tube output and transfusion requirements compared with FFP, although the effect sizes vary. Reported dosing ranged from fixed 500-4000 IU to weight-based 15-30 IU kg-1. Viscoelastic testing guides PCC administration; however, standardised thresholds are lacking. Limited data suggest that PCC may be more cost-effective than FFP, and serious adverse events appear to be rare. No study has directly compared different PCC dosing regimens or prophylactic use in high-risk patients. CONCLUSIONS: Substantial evidence gaps remain concerning the optimal dose, timing, viscoelastic targets, sequencing with fibrinogen concentrate, and health economic analyses of PCC use in cardiac surgery. High-quality randomised trials addressing these unanswered questions are warranted to refine the clinical guidelines.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
- No matching papers in this section with the selected filters.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.
No registered ongoing trials found.